摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1-phenyl-1-(3-pyridyl)methyl)-1-azabicyclo[2.2.2]octan-3-one | 1349823-95-5

中文名称
——
中文别名
——
英文名称
2-(1-phenyl-1-(3-pyridyl)methyl)-1-azabicyclo[2.2.2]octan-3-one
英文别名
2-(1-phenyl-1-(pyridin-3-yl)methyl)-1-azabicyclo[2.2.2]octan-3-one;2-(1-Phenyl-1-(3-pyridyl)methyl)-1-azabicyclo[2.2.2]octane-3-one;2-[phenyl(pyridin-3-yl)methyl]-1-azabicyclo[2.2.2]octan-3-one
2-(1-phenyl-1-(3-pyridyl)methyl)-1-azabicyclo[2.2.2]octan-3-one化学式
CAS
1349823-95-5
化学式
C19H20N2O
mdl
——
分子量
292.381
InChiKey
MPIIAOQPYJZFLX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    33.2
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
    申请人:——
    公开号:US20040002513A1
    公开(公告)日:2004-01-01
    The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the &agr;7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
    本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷类化合物,制备这些化合物的方法以及使用这些化合物进行治疗的方法。这些氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基是一个5-或6-成员环杂芳基,优选是3-吡啶基和5-嘧啶基,烷基通常是C1-4烷基。1-氮杂双环烷的3-位取代基是一个含有羰基的基团,例如酰胺、碳酸酯、代酰胺、碳酸酯、硫脲或类似功能基团。这些化合物在尼古丁乙酰胆碱受体(nAChRs)上表现出活性,特别是α7 nAChR亚型,并且对调节神经递质传递和与神经递质有关的配体释放具有用处。还公开了用于预防或治疗中枢神经系统(CNS)疾病等疾病和疾病的方法,这些疾病和疾病以正常神经递质传递的改变为特征。还公开了用于治疗炎症、自身免疫疾病、疼痛和过度新生血管化的方法,例如与肿瘤生长相关的新生血管化。
  • 3-Substituted-2(Arylalkyl)-1-Azabicycloalkanes and Methods of Use Thereof
    申请人:Mazurov A. Anatoly
    公开号:US20060247270A1
    公开(公告)日:2006-11-02
    The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
    本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷化合物,制备该化合物的方法以及使用该化合物的治疗方法。氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基基团是5-或6-成员环异芳基,优选为3-吡啶基和5-嘧啶基团,烷基通常为C1-4烷基。1-氮杂双环烷的3-位取代基是含有羰基基团的基团,例如酰胺、氨基甲酸酯、酰胺、氨基甲酸酯、硫脲或类似的官能团。该化合物在尼古丁乙酰胆碱受体(nAChRs)上表现出活性,特别是α7 nAChR亚型,并对调节神经递质和参与神经递质释放的配体具有用处。还公开了预防或治疗中枢神经系统(CNS)疾病等条件和障碍的方法,这些疾病的特征是正常神经递质发生改变。还公开了治疗炎症、自身免疫性疾病、疼痛和过度新生血管化的方法,例如与肿瘤生长有关的新生血管化。
  • 3-SUBSTITUTED-2(ARYLALKYL)-1- AZABICYCLOALKANES AND METHODS OF USE THEREOF
    申请人:Mazurov Anatoly A.
    公开号:US20080138287A1
    公开(公告)日:2008-06-12
    The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds, and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
    本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷类化合物、制备该类化合物的方法以及使用该类化合物的治疗方法。氮杂双环烷通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基是一个5-或6-成员环杂芳基,优选是3-吡啶基和5-嘧啶基,烷基通常是C1-4烷基。1-氮杂双环烷的3-位取代基是一种含有羰基基团的基团,例如酰胺、氨基甲酸酯、酰胺、氨基甲酸酯、硫脲或类似的官能团。该化合物在尼古丁乙酰胆碱受体(nAChRs)上表现出活性,特别是α7 nAChR亚型,并且对于调节神经递质和神经递质参与的配体的释放是有用的。还公开了预防或治疗条件和疾病的方法,包括中枢神经系统(CNS)疾病,这些疾病的特征是正常神经递质的改变。还公开了治疗炎症、自身免疫性疾病、疼痛和过度新血管生成的方法,例如与肿瘤生长相关的新血管生成。
  • 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF
    申请人:Mazurov Anatoly A.
    公开号:US20110071187A1
    公开(公告)日:2011-03-24
    The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
    本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷化合物,制备该化合物的方法以及使用该化合物的治疗方法。氮杂双环烷通常是氮杂双环庚烷,氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基基团是一个5-或6-成员环的杂芳基,优选为3-吡啶基和5-嘧啶基团,而烷基通常是C1-4烷基。在1-氮杂双环烷的3位取代基是含有羰基的基团,例如酰胺,氨基甲酸酯,酰胺,氨基甲酸酯,硫脲或类似的官能团。该化合物在尼古丁乙酰胆碱受体(nAChRs)上表现出活性,特别是α7 nAChR亚型,并且对调节神经递质和参与神经递质释放的配体具有用处。还公开了预防或治疗包括中枢神经系统(CNS)疾病在内的疾病和障碍的方法,这些疾病和障碍的特征是正常神经递质发生改变。还公开了治疗炎症、自身免疫性疾病、疼痛和过度新生血管化的方法,例如与肿瘤生长相关的新生血管化。
  • 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof
    申请人:Mazurov Anatoly A.
    公开号:US20120136024A1
    公开(公告)日:2012-05-31
    The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.
    本发明涉及3-取代-2-(芳基烷基)-1-氮杂双环烷化合物、制备这些化合物的方法以及使用这些化合物的治疗方法。这些氮杂双环烷化合物通常是氮杂双环庚烷、氮杂双环辛烷或氮杂双环壬烷。芳基烷基中的芳基基团是一个5-或6-成员环的杂芳族,优选为3-吡啶基和5-嘧啶基团,而烷基通常是C1-4烷基。1-氮杂双环烷的3-位取代基是一个含有羰基基团的基团,如酰胺、氨基甲酸酯、酰胺、氨基甲酸酯、硫脲或类似的官能团。这些化合物在尼古丁乙酰胆碱受体(nAChRs)中表现出活性,特别是α7 nAChR亚型,并且对于调节神经递质和参与神经递质释放的配体具有用途。还披露了防止或治疗中枢神经系统(CNS)紊乱等特征为正常神经递质改变的疾病和疾病的方法。还披露了用于治疗炎症、自身免疫性疾病、疼痛和过度新生血管化的方法,例如与肿瘤生长相关的过度新生血管化。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫